The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cells showed moderate to strong nuclear immunoreactivity. Strongest positivity was observed in testicular cancers and malignant melanomas.
Several prostate cancers dispalyed strong nuclear positivity while breast and urothelial cancer showed moderate cytoplasmic and nuclear staining. Remaining malignancies were weakly stained or negative.
exhibited moderate to strong nuclear immunoreactivity. Breast and urothelial cancer showed moderate nuclear and/or cytoplasmic staining in several cases. Most of the remaining malignant cells were negative or weakly positive.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
